Manufacturer of Highly-Modified Nucleic Acids and Parent Company Expand into New $50M Sorrento Mesa Facility
TriLink Biotechnologies and parent company Maravai LifeSciences are relocating within San Diego into a new facility that includes expanded space for GMP manufacturing of TriLink’s highly-modified nucleic acids. [TriLink Biotechnologies via Twitter]
A San Diego manufacturer of highly-modified nucleic acids and its parent company have concluded that development of RNA- and oligonucleotide-based therapeutics—as well as the region’s biopharma cluster—will both grow strongly enough in the near future to justify the companies’ recent $50-million investment in relocation and expansion within the city . . .
![UCLA team claims achievement will remove regulatory roadblock to future regenerative therapies.[Yang MingQi-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesJan2011Jan26_2011_1519803_OrangeBlueStemCells_StemCellsRegenMed4083471692-100x70.jpg "Animal-Free Culture System for Single-Cell Passaging of hESCs Developed")
